Oct 30, 2023 / 12:30PM GMT
Operator
Ladies and gentlemen, good morning. Welcome to Reviva Pharmaceuticals brilaroxazine program update conference call. (Operator Instructions)
As a reminder, this webcast is being recorded today, October 30, 2023. I will now turn the call over to Reviva's CEO, Lax Bhat. Please go ahead.
Lax Bhat - Reviva Pharmaceuticals Holdings, Inc. - CEO
Thank you. Good morning, and welcome everyone to the Reviva's brilaroxazine program update conference call. Earlier this morning, the Reviva issued a press release announcing positive topline results for the Phase 3 RECOVER study evaluating the efficacy, safety, and tolerability of brilaroxazine for adults with schizophrenia. A copy of this press release is available on the company's website through our SEC filings. Following our prepared remarks, we will hold a question-and-answer session with key opinion leader, Dr. Larry Ereshefsky, Chief Scientific Officer of Follow the Molecule, will join as well.
Please note that on today's call, we will be making forward-looking statements, which are based on current
Reviva Pharmaceuticals Holdings, Inc. Phase 3 RECOVER Topline Results Call Transcript
Oct 30, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers